Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

GSK Pharmaceuticals - Recovery from COVID-19 impact - ICICI Securities

Posted On: 2020-10-29 05:45:43

GlaxoSmithKline Pharmaceuticals Limited's (GSKP) Q2FY21 results were better than our estimates. Revenue remained flat YoY at Rs8.8bn (I-Sec: Rs8.2bn), EBITDA margin improved 130bps YoY (+570bps QoQ) to 23.3% (I-Sec: 22.9%) while adjusted PAT declined 27.8% YoY to Rs1.2bn (I-Sec: Rs1.3bn). Better than expected performance was driven by steady recovery in top brands with easing of lockdown. We expect this trend in recovery in the acute therapies to continue in the coming quarters. GSKP's exposure only to domestic formulations, strong balance sheet and strong brand equity augurs well for the company but current valuations seem fair, hence we maintain HOLD on the stock.

- Sequential growth as business recovers from COVID-19 impact: Revenue remained flat YoY but grew 35.6% QoQ during the quarter as acute therapies witnessed recovery with easing of lockdown. Company has informed that adjusting for the rationalisation process of tail end brands, YoY revenue growth stood at 3% in the quarter. While gross margin remained flat YoY and declined 210bps QoQ due to product mix, better efficiency and operating leverage resulted in the 130bps YoY and 570bps QoQ improvement in EBITDA margin to 23.3%, highest in several quarters. After considering all the strategic options, company has decided to proceed with the sale of the Vemgal manufacturing plant and has booked an exceptional expense of Rs641mn associated to it and classified it as an asset held for sale on the books.

- Key products performance: As per AIOCD data the GSKP has reported decline of 10.5%. Synflorix, T-Bact and Betnovate C have reported healthy YoY growth of 7.9%, 18.7% and 7.5% respectively for the quarter. However, Augmentin, Calpol, Ceftum and Betnesol have reported a YoY decline of 8.0%, 24.9%, 10.9% and 16.5% respectively. Infanrix Hexa continues its strong momentum with 18.1% YoY growth. Company has launched Fluarix Tetra, an inactivated quadrivalent influenza vaccine during the quarter.

- Outlook: FY21 estimates would optically appear lower due to Zinteac (ranitidine) sales in the base. However, we expect FY22 to report a strong growth both on revenue and earnings front. We expect 6.7% revenue and 12.1% PAT CAGR over FY20-FY23E driven by growth in power brands and key therapies like vaccines and VMN. Minimal capex requirement would aid cashflow generation of ~Rs20bn over the next three years.

- Valuations and risks: We reduce our revenue estimates by 2-4% for FY21E-FY23E to factor in lower sales. We also reduce our earnings estimates by 1-2% for FY22E-FY23E to factor in lower other income. We maintain HOLD with a revised target price of Rs1,511/share based on 40xSep'22E earnings (earlier: Rs1,539/share). Key downside risks: addition of key drugs in National List of Essential Medicines (NLEM), product concentration and government intervention. Key upside risks: better than expected performance in key products and new significant product launches.

Shares of GLAXOSMITHKLINE PHARMACEUTICALS LTD. was last trading in BSE at Rs.1482 as compared to the previous close of Rs. 1499.55. The total number of shares traded during the day was 2188 in over 467 trades.

The stock hit an intraday high of Rs. 1499.7 and intraday low of 1470. The net turnover during the day was Rs. 3237240.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Auto Sector - Monthly Volume Round-up - Nov 20 - Reliance Securities

What do brokerages say on Burger King India Limited's IPO?

The Phoenix Mills - Potential fund infusion may usher in growth - ICICI Securities

Godrej Agrovet - Beneficiary of 60% increase in palm oil prices - ICICI Securities

Automobiles (wholesale) - Wholesale dispatches rise amidst modest retail trends - ICICI Securities

Oil & Gas - Sector Update - Dec 2020 - ICICI Direct

Phoenix Mills (Buy): Asset monetisation at favourable terms... - ICICI Direct

Aditya Makharia's views on November Auto Sales Number for November 2020 - HDFC Securities

Burger King India - IPO Review - ICICI Direct

Quant Pick - LIC Housing Finance - ICICI Direct

Tech Mahindra - Analyst Meet Update - ICICI Direct

Gladiator Stocks - Crompton Greaves Consumer Electricals - ICICI Direct

Derivatives Monthly Outlook - Nifty support at 12800 for ongoing momentum...

Quant Pick - Sun Pharmaceuticals - ICICI Direct

Monetary Policy - Expectation from YES Securities

Sector Update on Asset Management Companies - Subdued but improvement expected - HDFC Securities

Pre Monetary Policy View - Dec, 2020 - Lakshmi Iyer, President and CIO (Debt) & Head Products, Kotak Mutual Fund

Maintain REDUCE on Siemens - Smart recovery priced in - HDFC Securities

Banking Sector Credit Trends - Growth continues to moderate - HDFC Securities

Q2 FY21 GDP: Light at the end of the tunnel - YES Securities

Siemens - Q4 FY20 Result Update - YES Securities

Super action in Home Loans - SBIN, ICICIBC, AXSB, HDFC and LICHF gaining share - YES Securities

Polymer price tracker - Dec 1, 2020 - PVC prices continue to tread higher - ICICI Securities

Bajaj Finance - Company Update - Dec 2020 - ICICI Direct

Siemens Ltd - Healthy revival in orders and margins - ICICI Securities

Covid Recovery Pulse - Nov 30, 2020 - Festive positivity continues in auto retails, e-way bill generation improves...

Derivatives Weekly View (November 27): Momentum expected to continue in broader markets with Nifty support at 12800...

Derivatives Strategy - Positional Option - ICICI Direct

Preview on RBI Monetary Policy - December 2020 - Shanti Ekambaram, Group President - Consumer Banking, Kotak Mahindra Bank

10 things you should know about Burger King India Limited

Views of HDFC Securities and Acuité Ratings & Research on Q2FY21 GDP Numbers

Rollover Report for November 2020 - December 2020: Angel Broking

Initiating Coverage on Godrej Properties - The housing factory - HDFC Securities

Burger King IPO - Angel Broking

Rollover Analysis - Record foreign inflows pushes Nifty to 13k - YES Securities

Ceramic tiles industry - Market share gains sustain for top branded players - ICICI Securities

Gas sector - CGD: Competition to hit margins, volumes and lead to derating - ICICI Securities

Cement - Prices resilient in Q3; consensus upgrades to continue - ICICI Securities

Specialty chemicals - Price trend in Sep-20 - ICICI Securities

Timken India - Q2FY21 Company Update - ICICI Direct

Upgrade in target price of IDFC First Bank - Angel Broking

Laurus Labs stake acquisition in Richore Lifesciences - Angel Broking

Shares of Lakshmi Vilas Bank (LVB) suspended from trading - Angel Broking

Initiating Coverage on Sundram Fasteners - Fastening growth - HDFC Securities

Astral Poly Technik - Scalability to further improve with storage tanks foray - ICICI Securities

Vardhman Special Steel - Q2FY21 Company Update - ICICI Direct

Initiating Coverage - Advanced Enzyme Technologies - ICICI Direct

L&T - Secures Large Contract - Nov 25, 2020 - Angel Broking

Alembic Pharmaceuticals - Tentative Approval for JV - Angel Broking

Drug launch by Lupin - Tacrolimus Capsules - Angel Broking

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019